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Purpose: We compared three rat strains to determine if different strains develop early-stage diabetic retinopathy or sensory
neuropathy at different rates.
Methods: Sprague Dawley, Lewis, and Wistar rats were made diabetic with streptozotocin. Diabetic and nondiabetic
animals had retinal vascular pathology measured at eight months of diabetes. The number of cells in the retinal ganglion
cell layer (GCL), retinal function (using electroretinography [ERG]), and retinal levels of inducible nitric oxide synthase
(iNOS), cyclooxygenase2 (COX2), and vascular endothelial growth factor (VEGF) were measured at four months of
diabetes. Tactile allodynia was assessed in hind paws at two months of diabetes.
Results: Diabetes of eight months’ duration resulted in a significant increase in retinal degenerate capillaries and pericyte
ghosts in Lewis and Wistar rats, but not in Sprague Dawley rats. A significant loss of cells in the GCL occurred only in
diabetic Lewis rats, whereas Wistar and Sprague Dawley rats showed little change. Diabetes-induced iNOS and VEGF
were statistically significant in all strains. Cyclooxygenase 2 (COX2) was significantly elevated in the Sprague Dawley
and Wistar strains. Lewis rats showed a similar trend, however, the results were not statistically significant. All strains
tended to show diabetes-induced impairment of dark-adapted b-wave amplitude, but only Sprague Dawley and Lewis
strains had a significant reduction in latency. All strains showed significant tactile allodynia in peripheral nerves.
Conclusions: At the durations studied, Lewis rats showed accelerated loss of both retinal capillaries and ganglion cells
in diabetes, whereas diabetic Wistar rats showed degeneration of the capillaries without significant neurodegeneration,
and Sprague Dawley rats showed neither lesion. Identification of strains that develop retinal lesions at different rates
should be of value in investigating the pathogenesis of retinopathy.
Hyperglycemia is accepted as a major determinant of
susceptibility  to  diabetic  retinopathy,  neuropathy,  and
nephropathy. Nevertheless, some patients in poor glycemic
control have escaped these complications and some patients
in good glycemic control have developed retinopathy [1].
Evidence indicates that the severity of diabetic retinopathy is
influenced by familial (possibly genetic) factors in Type 1
[1] and Type 2 diabetes [2]. Moreover, a possible role of
genetics in the development of retinopathy has been suggested
by monozygotic twin pairs showing greater concordance for
severity of retinopathy than dizygotic twin pairs with Type 2
diabetes [3], a higher prevalence of background retinopathy
in non-Hispanic than in Hispanic whites with Type 2 diabetes
[4],  and  differences  in  rates  of  nonproliferative  and
proliferative retinopathy in non-Ashkenazi versus Ashkenazi
Jews with Type 1 diabetes [5].
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Efforts  to  identify  genetic  contributors  to  retinopathy
have primarily involved the candidate gene approach. The
severity of retinopathy has been found to be associated with
gene polymorphisms of the aldose reductase pathway [6–17],
the  renin-angiotensin  system  [18–20],  and  the  human
leukocyte antigen (HLA) system [21–23]. However, these loci
have shown only modest associations with retinopathy and
findings  generally  have  not  been  replicated  in  other
population  groups.  Thus,  the  role  of  genetics  in  the
pathogenesis of diabetic retinopathy has remained difficult to
assess [24].
Animal models have been used to investigate genetic
factors  important  in  the  development  of  ocular  vascular
permeability [25] and neovascularization [26–28]. Although
diabetic rats have not been found to develop the advanced
stages  of  diabetic  retinopathy  seen  in  humans,  they  can
reproduce  lesions  of  early  diabetic  retinopathy,  including
structural (capillary degeneration, pericyte loss, ganglion cell
loss)  and  functional  (electroretinography  [ERG]
abnormalities) abnormalities [29–31]. Strain differences in
the  rate  of  development  of  kidney  disease  have  provided
insight into the pathogenesis of chronic kidney disease [32]
and kidney disease in diabetes [33], where susceptibility to
glomerulosclerosis in diabetes was judged to be at least in part
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1629inherited, with hyperglycemia serving principally as a trigger
in the development of the nephropathy.
We sought to investigate potential differences in the rate
at  which  early  stages  of  diabetic  retinopathy  and  sensory
hyperaesthesia develop in several rat strains. Previous studies
conducted using different rat strains have detected retinopathy
lesions  at  different  durations  of  diabetes  [34–40].  These
differences might simply have been due to differences in study
duration or in the severity of hyperglycemia between studies,
but  strain-dependent  differences  in  the  susceptibility  to
diabetic  retinopathy  was  also  a  possibility.  Thus,  we
conducted  a  side-by-side  comparison  of  retinopathy
development in three rat strains (Sprague Dawley, Lewis, and
Wistar). For comparison, we also evaluated the strains with
respect to the rate at which diabetes-induced tactile allodynia
developed.
METHODS
Animal models: Sprague Dawley, Lewis, and Wistar rats (200
g,  male)  were  purchased  from  Harlan  Laboratories
(Indianapolis, IN) and kept in ventilated microisolator units.
Insulin-deficient  diabetes  was  induced  with  streptozotocin
(55  mg/kg  BW)  after  an  overnight  fast.  All  experiments
followed  the  guidelines  set  forth  by  the  Association  for
Research  in  Vision  and  Ophthalmology  Resolution  on
Treatment of Animals in Research. The experiment did not
begin until two weeks after streptozotocin was administered
to ensure all animals were satisfactorily diabetic. All animals
were fed Teklad 7004 (Harlan Teklad, Indianapolis, IN). If
any animals lost weight at any time during the study, they were
given insulin (initially two units Neutral Protamine Hagedorn
insulin twice per week), with more given later if necessary to
achieve slow weight gain without preventing hyperglycemia
and glucosuria. Thus, diabetic rats were insulin-deficient, but
not grossly catabolic. Hyperglycemia was estimated every
two to three months by glycated hemoglobin (GHb) assay
using  a  VARIANT  kit  (Bio-Rad,  Hercules,  CA)  and  by
repeated blood glucose concentration assays. Diabetic and
age-matched  nondiabetic  controls  were  sacrificed  at  two
months  of  diabetes,  eight  months  of  diabetes  (for
histopathology),  and  four  months  (for  western  blots,
electroretinograms  [ERG],  and  neurodegeneration).  Eight
months’  duration  was  selected  for  the  assessment  of
histopathology because six to eight months is the earliest we
have  been  able  to  detect  a  diabetes-induced  increase  in
degenerate capillaries that achieves statistical significance,
thus making it a sensitive time to determine if the other strains
developed the pathology faster or slower.
Western  blot  analysis:  Retinas  were  sonicated  in
radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris
[pH=7.4], 1 mM EDTA, 150 mM NaCl, 1% NP-40, 0.1%
sodium dodecyl sulfate [SDS], 0.5% deoxycholic acid, 1 mM
phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin and 1 μg /
ml  aprotinin).  Proteins  were  fractionated  by  SDS–PAGE
(PAGE),  and  anti-inducible  nitric  oxide  synthase  (iNOS)
polyclonal  antibody  (1:1,000  dilution;  Transduction
Laboratories, Lexington, KY), cyclooxygenase-2 (COX-2)
polyclonal antiserum (1:500 dilution; Cayman Chemical, Ann
Arbor,  MI),  or  anti-vascular  endothelial  growth  factor
(VEGF)  polyclonal  antibody  (sc-152;  Santa  Cruz
Biotechnology) were administered. After extensive washing,
protein bands detected by the antibodies were visualized by
enhanced  chemiluminescence  and  evaluated  using
densitometry. Membranes were then stripped and re-probed
with antibody against actin (Sigma, St. Louis, MO) to confirm
equal protein loading. One retina from each of six animals per
experimental group was analyzed using western blots.
Isolation of retinal blood vessels: The retinal vasculature was
isolated  using  the  trypsin  digest  method,  as  previously
described [38,41–43]. Briefly, freshly isolated eyes were fixed
with 10% neural buffered formalin. Retinas were isolated,
washed in water overnight, and then incubated with 3% Difco
crude trypsin (BD BioSciences, Sparks, MD) at 37 °C for 1 h.
Non-vascular  cells  were  gently  bushed  away  from  the
vasculature and the isolated vasculature was laid out on glass
slides  and  air-dried  for  a  terminal  deoxynucleotidyl
transferase  dUTP  nick  end  labeling  (TUNEL)  assay  and
pathological examination.
Quantitation  of  acellular  capillaries  and  pericyte  ghosts:
Slides  were  stained  with  hematoxylin  and  periodic  acid-
Schiff,  dehydrated  and  coverslipped.  Acellular  capillaries
were quantified in four to seven field areas in the mid-retina
(200×  magnification)  in  a  masked  manner.  Acellular
capillaries  were  identified  as  capillary-sized  vessel  tubes
having  no  nuclei  anywhere  along  their  length,  and  were
reported per square millimeter of retinal area. Tubes having a
diameter <20% of the adjacent capillaries were identified as
strands and were not counted as acellular capillaries. Pericyte
ghosts were estimated from the prevalence of spaces in the
capillary  basement  membranes  from  which  pericytes  had
disappeared. At least 1,000 capillary cells in five field areas
in the mid-retina (400× magnification) were evaluated in a
masked  manner,  and  the  number  of  pericyte  ghosts  was
reported per 1,000 capillary cells. Ghosts on any acellular
vessel were excluded.
Neurodegeneration: Cells in the ganglion cell layer (GCL)
were  counted  as  a  parameter  of  diabetes-induced  retinal
neurodegeneration. Formalin-fixed eyes were embedded in
paraffin, sectioned sagittally through the retina (going through
the optic nerve), and stained with hematoxylin and eosion
(H&E). The number of cells in the GCL was counted per
250 μm retinal length in two areas (mid-retina and posterior
retina adjacent to the optic nerve) on both sides of the optic
nerve. Results from all four regions were expressed per unit
length and averaged.
Electroretinogram  (ERG):  Measurements  were  made  as
described previously [44] for five or six animals per group.
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1630Rats diabetic for four months (and nondiabetic controls) were
dark-adapted overnight, anesthetized intraperitoneally with
ketamine (4 mg/100 g BW) and xylazine (1 mg/100 g BW),
and placed on a heating pad during the recording session.
Pupils were dilated with 1% tropicamide, 1% cyclopentalate
hydrochloride,  and  2.5%  phenylephrine  hydrochloride.
Recordings were made using a stainless steel wire loop that
contacted  the  corneal  surface  through  a  thin  layer  of  1%
methylcellulose.  Needle  electrodes  placed  in  the  tail  and
cheek served as ground and reference electrodes, respectively.
Responses were amplified (1–1,000 Hz), averaged, and stored
on an LKC (UTAS) signal averaging system.
A dark-adapted intensity-response series was recorded
using a series of Ganzfeld flashes with intensities ranging
from –4.2 to 0.5 log cd sec/m2 to obtain rod-mediated retinal
responses. Cone-mediated responses were obtained to light
stimuli after 7 min light adaptation in which the animals were
exposed to a steady rod-desensitizing background light of 0.8
log cd/m2 presented in the Ganzfeld bowl. During steady rod
desensitization, cone-mediated responses to a series of flash
intensities were elicited (−0.22 to 0.52 log cd sec/m2). The
average  response  to  25  flashes  was  calculated  for  each
intensity.  The  amplitude  and  latency  of  individual  ERG
waveform components (the a- and b-waves) were measured
conventionally.  For  the  a-wave,  amplitude  was  measured
from the pre-stimulus baseline to the trough. For the b-wave,
amplitude was measured from the negative trough of the a-
wave  to  the  b-wave  peak.  Latency,  or  time-to-peak,  was
measured from stimulus onset to the a-wave trough and the b-
wave peak.
Tactile allodynia: This test was performed as described by
Chaplan et al. [45,46], as previously reported [47], at two
months of diabetes. Briefly, animals were placed in cages with
wire-mesh bottoms and the plantar surface of the hind paws
were  poked  through  the  mesh  using  Von  Frey  filaments
(Stoelting, Chicago, IL) to determine the 50% mechanical
threshold for the animal to lift or lick its paw. Lack of a
response after 5 s prompted the use of another filament of
different stiffness, and results from both hind paws for each
animal were averaged together. All measurements were made
by an investigator who was unaware of the treatment group
that individual animals were in.
Statistical  analysis:  Electroretinography  results  across
different light intensities and at individual intensities were
assessed by the Repeated Measures test and t-tests. All other
measures were analyzed using ANOVA (ANOVA) and Fisher
post-hoc  tests.  Differences  were  considered  statistically
significant when p values were <0.05.
RESULTS
Glycated hemoglobin and blood glucose in diabetic rats were
significantly greater than in nondiabetic controls in each of
the three strains studied. The severity of diabetes-induced
hyperglycemia was similar among all three strains (Table 1).
During  the  eight-month  experiment,  GHb  was  higher  in
Sprague  Dawley  and  Wistar  rats  than  in  Lewis  rats,  but
average  fasting  blood  glucose  over  the  course  of  the
experiment did not differ among groups. Diabetic rats were
treated with insulin so they did not lose weight, but with
amounts that were insufficient to maintain growth at the rate
shown by nondiabetic rats. Thus, bodyweights of all groups
of  diabetic  rats  remained  significantly  less  than  those  of
nondiabetic control rats (due to impaired growth, not weight
loss). Amounts of insulin injected tended to differ among
groups, but the differences were not statistically significant.
Eight months of diabetes did not induce degeneration of
retinal capillaries equally among the three strains tested. In
Lewis and Wistar rats, diabetes of eight months’ duration
caused a significant increase in the number of degenerate
(acellular)  capillaries  and  pericyte  ghosts  compared  to
nondiabetic controls (approximately threefold greater than
controls, each p<0.001). In contrast, the same duration of
diabetes did not cause a significant increase in the number of
degenerate capillaries or pericyte ghosts in Sprague Dawley
rats (Figure 1).
TABLE 1. STUDY OF NONDIABETIC AND DIABETIC PARAMETERS IN THREE STRAINS.






Nondiabetic ≥8 3.0±0.2 2.9±0.4 - 656±27
Diabetic ≥8 11.2±1.7 17.2±3.2 35.7±42.9 309±63
Lewis
Nondiabetic ≥8 2.9±0.6 2.9±0.2 - 555±48
Diabetic ≥8 10.1±1.3 13.3±2.7 22.5±24.9 307±25
Wistar
Nondiabetic ≥8 4.2±1.8 2.8±0.4 - 524±134
Diabetic ≥8 11.4±1.5 13.8±6.0 6.8±5.0 325±91
          *Average over the 8 month duration of study. GHb represents Glycated hemoglobin.
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1631Nonvascular cells of the retina have also been reported to
degenerate in diabetes. At four months of diabetes, the number
of cells in the GCL was counted in retinal cross-sections
through the optic nerve. As summarized in Figure 2, only
Lewis rats showed a significant reduction in the number of
cells in the GCL compared to nondiabetic controls (p<0.05).
The statistical significance of this reduction in the Lewis strain
was due to changes in the posterior retina only; none of the
strains showed a statistically significant reduction in numbers
of cells in the GCL in the mid-retina region (not shown). To
determine if strain differences in the rate of ganglion cell loss
influenced retinal function, we also measured retinal function
via light- and dark-adapted ERG in diabetic and nondiabetic
animals of all three strains. Lewis rats showed greater changes
in  amplitude  in  response  to  light  than  did  other  strains.
Diabetes of four months’ duration reduced the latency of rod-
Figure  1.  Comparison  of  capillary
degeneration  among  different  rat
strains. Diabetes-induced degeneration
of retinal capillaries (A) and pericyte
loss  (B)  occurred  more  slowly  in
Sprague Dawley rats than in Lewis or
Wistar  rats  diabetic  (Diab)  for  eight
months or in age-matched nondiabetic
(ND)  controls.  Both  lesions  were
counted in a masked fashion on trypsin-
digested microvessel preparations. All
groups  contained  more  than  eight
animals. Mean±SEM.
Figure  2.  Diabetes  of  four  months’
duration caused a significant decrease in
the number of cells in the GCL of the
retina in Lewis rats, but not Wistar rats.
Sprague Dawley diabetic rats tended to
show fewer cells in the GCL compared
to nondiabetic controls, but the results
were  not  statistically  significant.  All
groups  contained  more  than  eight
animals. Mean±SEM.
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1632mediated  b-waves  in  Sprague  Dawley  and  Lewis  strains
(p<0.05; Figure 3). Amplitudes of the dark-adapted b-waves
tended to be subnormal in diabetics of all three strains, but the
results  were  not  statistically  significant.  Comparisons  at
individual  light  intensities  (by  t-test)  indicated  that  rod-
mediated b-wave amplitudes in diabetics were significantly
different from normal only at higher intensities for all three
strains.  The  only  cone-mediated  b-wave  process  that  was
significantly altered by diabetes was amplitude, only at the
highest intensity, in Sprague Dawley and Lewis strains (not
shown).
Inflammatory  processes  have  been  postulated  to
contribute to the development of diabetic retinopathy [48,
49]. In an effort to identify possible biochemical causes of the
observed strain differences, we measured several biochemical
parameters involved in the inflammatory process. Compared
to age-matched nondiabetic controls for each of the strains,
diabetes tended to increase expression of iNOS, COX2, and
VEGF in all three strains (Figure 4). The diabetes-induced
increase in protein expression was statistically significant for
all  strains  with  respect  to  iNOS  and  VEGF,  and  was
significantly increased in Sprague Dawley and Wistar strains
for COX2. Cyclooxygenase 2 expression tended to increase
in diabetic Lewis rats, but the increase was not statistically
significant at this duration of diabetes.
Rats diabetic for two months detected peripheral sensory
stimulation at significantly lower pressures than nondiabetic
animals in all three rat strains (Figure 5; p<0.01). Despite the
difference among strains in the rate of development of retinal
Figure 3. Diabetes of 4 months duration
reduced the latency of rod-mediated b-
waves in Sprague Dawley and Lewis
strains,  but  not  Wistar  rats.
Electroretinogram assessed responses to
a  bright  flash  in  diabetic  rats  (solid
circles)  or  age-matched  nondiabetic
controls  (hollow  circles).  Peak
amplitudes of rod mediated a- and b-
wave latency (A) and amplitude (B) are
graphed  as  a  function  of  strobe  flash
intensity.  Amplitude  tended  to  be
subnormal in all 3 diabetic strains, but
results achieved statistical significance
mainly at higher intensities. Group sizes
were 5 for all measurements. †p<0.05 by
repeated measures test. *p<0.05 by t-
test between nondiabetic and diabetic at
specified flash intensity. Mean±SEM.
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1633lesions, little or no difference among strains was noted with
regard to the severity of diabetes-induced tactile allodynia.
DISCUSSION
In the present study, three different rat strains were compared
with  respect  to  their  susceptibility  to  develop  early-stage
diabetic retinopathy. These vascular and neural abnormalities
also develop in diabetic humans, and evidence suggests that
they  contribute  to  the  later  development  of  clinically
meaningful visual impairment in diabetic patients. We found
that  diabetes-induced  degeneration  of  retinal  capillaries
occurred relatively faster in Lewis and Wistar strains than in
Sprague  Dawley  rats.  Diabetes-induced  degeneration  of
retinal ganglion cells likewise developed at different rates
among the strains, but the results were not the same as for
capillary degeneration. Only Lewis rats showed a significant
loss of retinal ganglion cells within four months of diabetes.
Importantly,  these  strain  differences  in  susceptibility  or
resistance to retinal vascular and neuronal lesions in diabetes
seem not to be attributable to differences in glycemia.
Differences between rat strains have also been reported
for other parameters, including susceptibility to blood-retinal
barrier breakdown in diabetes. Diabetic Brown Norway rats
developed sustained vascular hyperpermeability in the retina
over a period of 16 weeks, whereas diabetic Sprague Dawley
rats showed only transient hyperpermeability immediately
following  diabetes  onset  [25].  The  strain  difference  in
vascular leakage between diabetic rats of the two strains was
partially ascribed to different VEGF expression and VEGF
signaling in these strains. In our studies, VEGF expression
was significantly increased in all three strains, and thus could
not be clearly correlated with the rate at which the strains
developed vascular pathology in diabetes. Sprague Dawley
and Lewis strains have also been shown to respond differently
in studies of oxygen-induced retinopathy, hyperoxia causing
significantly larger areas of retinal avascularity in Lewis rats
compared to Sprague Dawley rats [50]. Differences between
these two strains have also been reported with respect to
neuropathy and pain, immunoglobulin A (IgA) nephropathy,
and  inflammation  [51–60].  Previous  investigators  have
reported a 10%–15% loss of thickness of the inner plexiform
layer and subnormal thickness of the photoreceptor layer one
month after the induction of diabetes in Sprague Dawley and
Brown Norway rats [61].
At the durations of diabetes studied, Lewis rats showed
accelerated  loss  of  both  capillaries  and  ganglion  cells  in
diabetes, whereas diabetic Wistar rats showed degeneration
of the capillaries without significant neurodegeneration and
Sprague Dawley rats showed neither. Although degeneration
of retinal capillaries and ganglion cells in diabetes developed
slower in Sprague Dawley rats than in the other strains tested,
both lesions nevertheless do eventually develop in Sprague
Dawley rats at longer durations of diabetes [35,38,39,62].
Figure 4. Comparison of diabetes-induced changes in inflammatory
molecules  among  rat  strains.  Diabetes  of  four  months’  duration
increased retinal expression of (A) inducible nitric oxide synthase
(iNOS), (B) cyclooxygenase 2 (COX2), and (C) vascular endothelial
growth factor (VEGF) in Sprague Dawley, Lewis, and Wistar rats.
All diabetes-induced increases were statistically significant, except
that  COX2  expression  only  tended  to  increase  in  Lewis  rats.
Expression data are expressed as a ratio to expression of actin in the
same sample. Groups contained six animals per group. Mean±SEM.
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Thus,  these  studies  apparently  demonstrate  geneticdifferences among the strains that influence the rate at which
retinal cells degenerate. However, whether the final extent of
degeneration likewise differs has yet to be determined.
Retinal function was also disturbed in diabetic rats of all
three strains, but differences among the strains were again
apparent. In contrast to findings of vascular and neuronal
degeneration, diabetics from the Sprague Dawley and Lewis
strains showed more abnormalities in rod-mediated retinal
function than did those from the Wistar strain at the duration
of diabetes studied. Whether development of these functional
defects are related to or predict the rate at which vascular and
neural cells degenerate in diabetes cannot be learned from the
present  study.  We  previously  [63]  found  that  Lewis  rats
diabetic for a longer duration (nine months) had different
responses  than  reported  herein  (latency  response  was  not
significantly altered in diabetes), raising the possibility that
the  disturbances  of  retinal  function  might  change  with
increasing duration of diabetes.
Differences in the severity of hyperglycemia or insulin
deficiency  between  strains  obviously  might  influence  the
development rate of pathology. The observed differences in
GHb between the diabetics of each strain seem modest, but
even if one assumes that those differences are important, the
strain with the apparently highest hyperglycemia (Sprague
Dawley) developed the pathology the slowest, and the strain
with the apparently lower hyperglycemia (Lewis) developed
the pathology fastest. The amount of insulin administered to
maintain that level of hyperglycemia also seemed different
between strains. Insulin can directly affect retinal cells [64],
but  the  amounts  of  insulin  administered  to  the  strains
developing capillary degeneration fastest (Lewis) and slowest
Figure 5. Diabetes also affects the peripheral nervous system. Two
months of diabetes results in hypersensitivity to light touch (tactile
allodynia) in the hind paws of all three rat strains studied (Sprague
Dawley,  Lewis,  and  Wistar  rats).  Groups  contained  at  least  six
animals per group. Mean±SEM.
(Sprague Dawley) were not significantly different. Thus, we
conclude that differences in hyperglycemia and the amount of
insulin administered are not likely to account for the observed
differences  in  histopathological  development  in  these
animals.
Retinas from diabetic animals exhibit biochemical and
physiologic abnormalities consistent with inflammation [43,
63,65–69],  and  we  and  others  have  postulated  that
inflammatory  processes  play  an  important  role  in  the
pathogenesis  of  diabetic  retinopathy  [48,49].  Intravitreal
administration of the proinflammatory growth factor VEGF
has been observed to cause diabetic-like capillary lesions,
including capillary leakage and closure, microaneurysms, and
intraretinal  hemorrhages  [70–72].  The  extent  to  which
diabetes  induced  retinal  levels  of  the  proinflammatory
molecules iNOS, COX2, and VEGF, however, was similar
among the three strains studied. Thus, expression levels of at
least these inflammatory molecules in the retina seems not to
account for the observed strain differences in the rates at
which diabetes-induced retinal cell degeneration develops, at
least at the duration of diabetes when they were measured. The
amount of these proteins expressed might have been quite
different  at  different  durations  of  diabetes.  Although
inhibition  of  inflammatory-like  processes  inhibit
development of the retinopathy in animal models [39,42,43,
48,63,73–77], other factors, including perhaps blood pressure,
lipid levels, and genetic differences, likely also contribute and
perhaps are even more important than inflammatory changes
in determining the rate at which the retinopathy develops.
Diabetic  neuropathy  is  one  of  the  most  common
complications  of  diabetes  and  includes  clinical  symptoms
such as tactile allodynia (nociceptive responses to normally
innocuous stimuli), hyperalgesia (augmented pain response to
painful stimuli), and spontaneous pain. Mechanical allodynia,
assessed  using  Von  Frey  filaments,  develops  rapidly  in
diabetic rats and can be inhibited by a variety of therapies,
including good glycemic control [46,78]. Although diabetes
appreciably enhanced sensitivity to sensory stimuli in our
studies, we did not observe differences in the rate at which
this  complication  developed  among  the  different  strains
tested.
Genetic differences between animal strains or genetically
different  populations  have  been  used  to  identify  genes
responsible for pathology in other diseases (phenotype-to-
gene  approach).  The  genetic  factors  underlying  the
phenotypic  variation  among  animal  strains  or  populations
have been mapped by quantitative trait locus (QTL) analysis,
and  genes  for  several  QTLs  (such  as  obesity,  insulin
resistance,  taste,  susceptibility  to  cytomegalovirus,  and
hypertension) have been identified [79–84]. This or similar
approaches might be used successfully to identify genes that
contribute to susceptibility to diabetic retinopathy. The data
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such experiments.
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